What does increasing regulatory oversight mean for the pharma supply chain?
The Network Effect
AUGUST 26, 2014
Within a decade, the number of FDA warning letters sent to medical device manufacturers has increased threefold, from 61 letters in 2002 to 181 in 2012 (EC A 2012). China published new GMP guidelines in 2012 and called on pharmaceutical companies to pursue GMP certification by the end of 2013.
Let's personalize your content